Table 3.

Clinically relevant genetic variants of members of the SLC28A and SLC29A families of SLC in the pharmacokinetics, efficacy, or toxicity of antitumor drugs

Variant		Drug	Targeted tumor	Alteration	Study size	Ethnicity	Ref.
SLC28A1	rs2242046	Gemcitabine	Non-small cell lung cancer	Toxicity	53	East Asian	[120]
	rs3825876	Gemcitabine	Pancreatic cancer	Toxicity	294	European	[121]
SLC28A2	rs11854484	Gemcitabine	Non-small cell lung cancer	Efficacy	53	East Asian	[120]
SLC28A3	rs7867504	Gemcitabine	Solid tumors	Pharmacokinetics	40	American	[122]
SLC29A1	rs9394992	Tipiracil, trifluridine	Colorectal carcinoma	Efficacy	179	Multiple groups	[123]
		Gemcitabine	Pancreatic cancer	Toxicity	149	Multiple groups	[124]
	rs747199	Gemcitabine	Breast carcinoma	Efficacy	85	East Asian	[125]
	rs760370	Gemcitabine	Breast carcinoma	Efficacy	85	East Asian	[125]
		Gemcitabine	Pancreatic cancer	Efficacy	149	Multiple groups	[124]
		Tipiracil, trifluridine	Colorectal carcinoma	Efficacy	179	Multiple groups	[123]
SLC29A3	rs780668	Gemcitabine	Non-small cell lung cancer	Efficacy	88	Multiple groups	[126]

SLC: Solute carrier.